ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS
Michael Platten(German Cancer Research Center), Wolfgang Wick(German Cancer Research Center), Stefan Stevanović(University of Tübingen), Michael Schmitt(German Cancer Research Center), Lukas Bunse(German Cancer Research Center), J. Hense(Essen University Hospital), Irini Karapanagiotou‐Schenkel(German Cancer Research Center), Astrid Weyerbrock(University of Freiburg), Dennis Riehl(Johannes Gutenberg University Mainz), Antje Wick(Heidelberg University), Khwab Sanghvi(Heidelberg University), Martin Misch(Humboldt-Universität zu Berlin), Andreas von Deimling(German Cancer Research Center), Inga Harting(Heidelberg University), Daniela Schilling(TUM Klinikum), Felix Sahm(German Cancer Research Center), Joachim P. Steinbach(Goethe University Frankfurt), Ghazaleh Tabatabai(Goethe University Frankfurt), Dietmar Krex, Edward Green(Heidelberg University), Theresa Bunse(German Cancer Research Center)
Cited by 26
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
MHC ligands and peptide motifs: first listing
|Immunogenetics|1995|1.6k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k